1. Incretin-based therapy: a new horizon in diabetes management.
- Author
-
Zarei, Malek, Sahebi Vaighan, Navideh, Farjoo, Mohammad Hadi, Talebi, Soosan, and Zarei, Mohammad
- Subjects
CD26 antigen ,PEPTIDE hormones ,DIABETES complications ,GLUCAGON-like peptide-1 agonists ,GASTROINTESTINAL hormones ,GLUCAGON receptors - Abstract
Diabetes mellitus, a metabolic syndrome characterized by hyperglycemia and insulin dysfunction, often leads to serious complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease. Incretins, gut peptide hormones released post-nutrient intake, have shown promising therapeutic effects on these complications due to their wide-ranging biological impacts on various body systems. This review focuses on the role of incretin-based therapies, particularly Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, in managing diabetes and its complications. We also discuss the potential of novel agents like semaglutide, a recently approved oral compound, and dual/triple agonists targeting GLP-1/GIP, GLP-1/glucagon, and GLP-1/GIP/glucagon receptors, which are currently under investigation. The review aims to provide a comprehensive understanding of the beneficial impacts of natural incretins and the therapeutic potential of incretin-based therapies in diabetes management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF